Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
69 results about "Co-Transporters" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cotransporters are a subcategory of membrane transport proteins (transporters) that couple the favorable movement of one molecule with its concentration gradient and unfavorable movement of another molecule against its concentration gradient.
Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
InactiveUS20060025387A1Suppressing neuronal excitabilityFunction increaseBiocideSalicyclic acid active ingredientsDiseaseNervous system
The present invention relates to methods and compositions for treating disorders of the central and / or peripheral nervous system by administering agents that are effective in reducing the effective amount, inactivating, and / or inhibiting the activity of a Na+—K+—2CT (NKCC) cotransporter. In certain embodiments, the Na+—K+—2Cl− co-transporter is NKCC1.
Owner:NEUROTHERAPEUTICS PHARMA
Process for Production of Azulene Derivatives and Intermediates for the Synthesis of the Same
InactiveUS20070293690A1High yieldEasy to operateSaccharide with carbocyclic radicalsSugar derivativesC-glycosideAcyl group
A process for producing an azulene derivative useful as a Na+-glucose cotransporter inhibitor, which is high in yield, is simple in operation, is low in cost, is suited for environmental protection, and is advantageous industrially, the process being characterized by reducing and deprotecting at least one compound selected from penta-acyl compounds and tetra-acyl compounds or salts thereof to obtain a C-glycoside compound; and a useful intermediate for synthesis of such an azulene derivative, obtained in the course of the above process.
Owner:ASTELLAS PHARMA INC +1
Inhibitors of sodium glucose co-transporter 2 and methods of their use
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.
Owner:LEXICON PHARM INC
Method of treating migraine headache without aura
InactiveUS7214711B2Function increaseUseful in treatmentBiocideNervous disorderNervous systemTreatment pain
Owner:NEUROTHERAPEUTICS PHARMA
SGLT-2 inhibitors, methods of making them, and uses thereof
Owner:ALBANY MOLECULAR RESEARCH INC
Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
InactiveUS20050267103A1Reduce neuronal hypersynchronyAvoiding unwanted side effectAnhydride/acid/halide active ingredientsHeterocyclic compound active ingredientsNeuropathic painTranslocator protein
The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and / or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1.
Owner:NEUROPRO THERAPEUTICS
Inhibitors of sodium glucose co-transporter 2 and methods of their use
ActiveCN101343296AInhibitory activityOrganic active ingredientsSugar derivativesDiseaseDiabetes mellitus
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.
Owner:LEXICON PHARM INC
Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use
Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity.
Owner:LEXICON PHARM INC
Glucoside derivate
The invention belongs to the field of medical technology, and particularly relates to a glucoside derivate shown as a formula (I), and a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate, in particular to a glucoside derivate which is served as a sodium-glucose co-transporter (SGLT) inhibitor, a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate. The glucoside derivate provided by the invention can be used for treating diabetes mellitus such as insulin dependent diabetes mellitus (I type diabetes mellitus) and non-insulin dependent diabetes mellitus (II type diabetes mellitus), and also can be applied to treating insulin resistance diseases and various diseases relevant to diabetes mellitus of fat, and preventing such diseases, wherein R1, R2, R3, R4, R5, R6, R7, R7a, R7b, R7c, X, n and A are defined as shown in the specification.
Owner:SHANDONG XUANZHU PHARMA TECH CO LTD
Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat
The present invention provides pharmaceutical compositions useful as agents for the inhibition of progression of diseases associated with abnormal accumulation of liver lipids. In particular, the pharmaceutical compositions of the present invention which comprise as an active ingredient a sodium / glucose co-transporter 2 inhibitor are highly suitable as an agent for the inhibition of progression of not only common fatty liver but also non-alcholic fatty liver disease (NAFL), non-alcholic steatohepatitis (NASH), hypernutritive fatty liver, diabetic fatty liver, alcholic fatty liver disease toxic fatty liver or the like.
Owner:KISSEI PHARMA
Glycoside derivatives and uses thereof
Owner:NOVARTIS AG
Inhibitors of sodium glucose co-transporter 2 and methods of their use
ActiveUS7781577B2Saccharide with heterocyclic radicalsSaccharide with carbocyclic radicalsDiabetes mellitusD-Glucose
Owner:LEXICON PHARM INC
1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof
InactiveCN103965267AImprove stabilityGood for medicineSaccharide with carbocyclic radicalsSugar derivativesBenzeneD-Glucose
The invention discloses an eutectic compound of 1-(beta-D-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and L-phenylalanine and a preparation method thereof. Specifically speaking, the invention discloses the eutectic compound shown in a formula (Ia) and formed by L-phenylalanine and a sodium-glucose co-transporter 2 (SGLT-2) inhibitor shown in a formula (I), i.e., 1-(beta-D-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene. The XRD characteristic peaks of the eutectic compound are shown in a figure 1. The preparation method comprises the following steps: mixing an aqueous solution of L-phenylalanine with an ethanol solution of the compound I; carrying out heating for dissolving of the two substances; then carrying out stirring, cooling and crystallization; and subjecting a filtrate to ethanol water recrystallization so as to obtain the eutectic compound. The formula (I) and the formula (Ia) are described in the specification.
![1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/6e791490-d6a2-4dbd-9497-624e0cd288bb/HDA00002773789200011.png "1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof")
![1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/6e791490-d6a2-4dbd-9497-624e0cd288bb/FDA00002773789000011.png "1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof")
![1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof](https://images-eureka-patsnap-com.libproxy1.nus.edu.sg/patent_img/6e791490-d6a2-4dbd-9497-624e0cd288bb/FDA00002773789000012.png "1-(beta-d-pyranoglucosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene and l-phenylalanine eutectic compound and preparation method thereof")
Owner:JIANGSU HANSOH PHARMA CO LTD +1
Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
Owner:LEXICON PHARM INC
Nanometer-scale optical imaging by the modulation tracking (MT) method
ActiveUS20120250000A1High quality imagingOptical rangefindersMaterial analysis by optical meansOpossumCell adhesion
An optical imaging method based on a feedback principle in which the specific scan pattern is adapted according to the shape of the sample. The feedback approach produces nanometer-resolved three dimensional images of very small and moving features in live cells and in a matter of seconds. Images of microvilli in live cultured opossum kidney cells expressing NaPi co-transporter proteins with different GFP constructs and images of cell protrusions in a collagen matrix are produced with a resolution of about 20 nm. Along cell protrusions in three dimensional cellular adhesions could be identified to the extracellular matrix.
Owner:RGT UNIV OF CALIFORNIA
Targeting the EGFR-SGLT1 Interaction for Cancer Therapy
ActiveCN105358173APeptide/protein ingredientsDigestive systemCancer targetingNa+/Glucose Cotransporter 1
A compound can destabilize a binding interaction between an epidermal growth factor receptor (EGFR) and a sodium / glucose co-transporter 1 (SGLT 1). In one embodiment, the compound is a peptide derived from the interacting domain of EGFR. In another embodiment, the peptide is administered to a patient to treat cancer.
Owner:UNIV HOUSTON SYST
Sglt-2 inhibitors, methods of making them, and uses thereof
InactiveUS20110237527A1Improve the level ofHigh levelSaccharide with heterocyclic radicalsBiocideDiseaseDecreased sodium
The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.
Owner:ALBANY MOLECULAR RESEARCH INC
Optically pure benzyl-4-chlorophenyl-c-glucoside derivative
ActiveUS20150191502A1High selectivitySafely used to treatEsterified saccharide compoundsBiocideDiseaseInsulin dependent diabetes
The present invention belongs to the field of pharmaceutical technology, more specifically relates to optically pure benzyl-4-chlorophenyl-C-glucoside derivatives represented by formulae (II) and (III), a process for preparing these compounds and intermediates thereof, a pharmaceutical formulation and a pharmaceutical composition containing these compounds, and the use of the optically pure benzyl-4-chlorophenyl-C-glucoside derivative as a sodium glucose co-transporter (SGLT) inhibitor in manufacture of a medicament for treating and / or preventing diabetes mellitus (including insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus) or diabetes-associated diseases (including insulin resistance disease and obesity)
Owner:JI LIN HUI SHENG BIO PHARMACEUTICAL CO LTD +1
SGLT2 (Sodium-glucose co-transporter 2) inhibitor and use thereof
InactiveCN103446170AHas inhibitory effectMetabolism disorderHeterocyclic compound active ingredientsSGLT2 InhibitorMedicine
The invention relates to the field of medicinal chemistry, and particularly relates to compounds (1-25) and a medicinal use of a medicinal composition containing the compounds, in particular a use as an SGLT2 (Sodium-glucose co-transporter 2) inhibitor.
Owner:CHINA PHARM UNIV
Crystal form of glucopyranose derivative
ActiveCN106674294AReduce absorptionPromote absorptionOrganic active ingredientsSenses disorderDiabetes mellitusDisease
The invention relates to a crystal form of a glucopyranose derivative serving as a sodium-glucose co-transporter (SGLT) inhibitor, a preparation method thereof and a pharmaceutical application thereof, and also relates to a medicine compound containing the crystal form and the application thereof for preparing drugs for treating diabetes and / or diseases related to diabetes.
Owner:YICHANG HEC CHANGJIANG PHARMA CO LTD
C-aryl glucoside SGLT2 (Sodium-Glucose Co-transporter 2) inhibitor
The invention relates to the field of medicines related to diabetes mellitus and particularly relates to a 2-type sodium-glucose co-transporter (SGLT2) inhibitor with a multi-aryl glucoside structure and shown as the specification, a preparation method thereof, a medicine composition taking the compound as an active components and an application thereof in preparing medicines for resisting diabetes mellitus.
Owner:CHINA PHARM UNIV
Method for improving drought tolerance of plants by improving photorespiration
ActiveCN110564760AImprove photosynthetic efficiencyIncrease biomassOxidoreductasesPlant peptidesMalate synthaseGlycolic acid dehydrogenase
The invention discloses a method for improving drought tolerance of plants by improving photorespiration, which comprises the following steps: inhibiting or knocking out bile acid sodium cotransportergenes in the plants, and simultaneously overexpressing glyoxylate dehydrogenase genes and malate synthase genes. The method creatively discovers that the expression of the BASS6 gene in the plant isinhibited; glycolic acid dehydrogenase genes and malic acid synthase genes are overexpressed in chloroplast, light respiration can be remarkably reduced, the photosynthetic efficiency of plants can beimproved, the biomass or yield of the plants can be increased, more importantly, the drought tolerance of the transgenic plants is remarkably higher than that of plants inhibiting PLGG1 gene expression, and the drought tolerance is improved by 5%-50%.
Owner:ZHEJIANG UNIV
Construction body for producing carbohydrate compound by virtue of synechococcus UTEX2973, strain and method
ActiveCN107236754ADoes not increase emissionsBacteriaMicroorganism based processesBiotechnologyPhylum Cyanobacteria
The invention relates to the bio-manufacturing field and particularly relates to a construction body for producing carbohydrate compound by virtue of synechococcus UTEX2973, a strain and a method. The construction body contains a promoter, a proton / saccharose synergetic transport protein gene, an antibiotic resistance gene and a homologous arm, wherein the promoter has activity in synechococcus UTEX2973, the proton / saccharose synergetic transport protein gene is controlled by the promoter, the antibiotic resistance gene is used for screening a transformant, and the homologous arm is used for homologously integrating genomes. The carbohydrate compound is synthesized by immobilizing carbon dioxide by virtue of solar energy in a photosynthetic microorganism, namely cyanobacteria, the energy for synthesizing carbohydrates is from the solar energy, and a carbon source is from carbon dioxide. Therefore, a biology base product prepared by virtue of the method is not restricted by insufficient raw materials, the carbon emission is not increased during the use of the biology base product, and the biology base product is a true zero-emission biology base product.
Owner:QINGDAO INST OF BIOENERGY & BIOPROCESS TECH CHINESE ACADEMY OF SCI
Inhibitors of sodium glucose co-transporter 2 and methods of their use
ActiveCN101343296BInhibitory activityOrganic active ingredientsSugar derivativesDiabetes mellitusDisease
Owner:LEXICON PHARM INC
Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease
ActiveUS8845999B2Improve assessmentIn-vivo radioactive preparationsSugar derivativesMedicineGlucose polymers
Owner:RGT UNIV OF CALIFORNIA
Treatment of tinnitus through modulation of chloride co-transporter nkcc1 in the auditory system
InactiveUS20160271098A1Suitable for treatmentCompound screeningSenses disorderActive agentPharmaceutical drug
The present invention relates to the treatment of prevention of tinnitus. More precisely, the present invention relates to a compound modulating chloride co-transporter NKCC1 (chloride co-transporter modulator) for use in the treatment of tinnitus. In addition, the present invention concerns pharmaceutical composition comprising such an NKCC1 chloride co-transporter modulator as an active agent a method for the treatment or prevention of tinnitus by administering such a chloride co-transporter modulator, and a screening method for the identification and characterization of compounds capable of modulation chloride co-transporter NKCC1.
Owner:OTOLANUM
Edible composition
ActiveUS20140107052A1Reducing amplitude responseReducing glycemic responseBiocideCarbohydrate active ingredientsSucroseLactase
Foods or meals high in available carbohydrate such as sucrose or starch increase postprandial blood glucose concentrations. Repeated high post-prandial plasma glucose “spikes” are associated with an increased risk of developing type II diabetes. Unregulated glycemic excursions are undesirable, and any reduction or “blunting” of the post-prandial glucose concentration in blood is potentially beneficial. This invention relates to an edible composition for delay of intestinal glucose uptake through synergistic inhibition of both active sodium glucose co-transporter 1 (SGLT1) and passive glucose transporter 2 (GLUT2) leading to flattening or blunting of the post-prandial glucose peak. Thus in a first aspect of the invention, an edible composition is provided, the composition comprising at least 5% dry weight at least one flavonoid aglycone and at least 5% dry weight at least one flavonoid glucoside, wherein the flavonoid glucoside is at least 20%, preferably at least 40%, most preferably at least 60% more resistant to hydrolysis by lactase phloridzin hydrolase than quercetin-4-glucoside, and wherein the flavonoid aglycone is a GLUT 2 inhibitor and the flavonoid glucoside is a SGLT 1 inhibitor.
Owner:CONOPCO INC D B A UNILEVER
Process for production of azulene derivatives and intermediates for the synthesis of the same
InactiveCN1984898ASuitable for protectionHigh yieldSaccharide with carbocyclic radicalsSugar derivativesC-glycosideC glycosides
Owner:ASTELLAS PHARMA INC +1
Sulfate of intestine type 2B sodium phosphate co-transporter inhibitor and its crystal form
ActiveCN107082773AMeet the limit requirementsImprove stabilityOrganic active ingredientsMetabolism disorderSodium phosphatesSulfate
The invention relates to a sulfate of an intestine type 2B sodium phosphate co-transporter inhibitor and its crystal form and particularly relates to N1-methyl-N1-(2-morpholin-ethyl)-N3-(3-(4-phenethylphenylcarbamoyl)-4, 5, 6, 7-tetrahydrobenzo[b]thiophene-2-yl)-m-phthalamide sulfate (compound shown in the formula (I)) and its type I crystal and preparation method. The type I crystal of the compound shown in the formula (I) has good chemical stability and crystal form stability and the used crystallization solvent has low toxicity and low residue content and can be used for clinical treatment.
Owner:JIANGSU HENGRUI MEDICINE CO LTD +1
Novel SGLT2 inhibitor compounds and pharmaceutical composition thereof
InactiveCN104672227AGood physical and chemical propertiesLow toxicityOrganic active ingredientsSenses disorderAcute hyperglycaemiaDiabetic retinopathy
The invention discloses novel SGLT2 inhibitor compounds shown in a formula (I), pharmaceutically acceptable salts, easily hydrolyzed pre-drug esters or isomers and a pharmaceutical composition which contains the compounds as an inhibitor of a sodium-glucose co-transporter (SGLT). The pharmaceutical composition is used for treating or delaying related diseases such as diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, insulin resistance, hyperglycemia, hyperinsulinemia, rise of fatty acid or glycerinum, hyperlipemia, obesity, hypertriglyceridemia, X syndrome, diabetic complications, atherosclerosis, hypertension and the like. The formula is shown in the description.
Owner:JIANGSU ATOM BIOSCI & PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com